Release Date: July 29, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- VK2735 Phase III VANQUISH program is fully enrolled and advancing on track, with both obesity and obesity/type 2 diabetes trials progressing.
- Oral VK2735 Phase III trials expected to initiate in Q4 2026, positioning it as a potential first-to-market oral dual GLP-1/GIP agonist.
- Novel maintenance dosing study for VK2735 is nearing completion, with results expected later this quarter, exploring less frequent dosing regimens.
- New dual amylin and calcitonin receptor agonist, VK3019, entered Phase I clinical development, expanding the obesity pipeline.
- Strong balance sheet with over $500 million in cash, expected to fund key milestones including completion of Phase III trials.
- Key executive hires, including a Chief Commercial Officer and Chief Medical Officer, strengthen commercial and clinical leadership.
Negative Points
- Net loss increased significantly to $128.1 million in Q2 2026 from $65.6 million in Q2 2025, driven by higher R&D expenses.
- Cash and short-term investments decreased to $502 million from $706 million at year-end 2025, reflecting high cash burn.
- Phase III oral VK2735 trial design details remain undisclosed, creating uncertainty about dosing and enrollment targets.
- Maintenance study results may be difficult to compare with competitor trials due to different study designs and shorter duration.
- Early-stage VK3019 program faces uncertainty, with no clear go/no-go decision criteria until Phase I MAD data in 2027.
Q & A Highlights
Here are the key highlights from Viking Therapeutics Inc VKTX's Q2 2026 earnings call, focusing on the most significant Q&A exchanges.Q: Regarding the maintenance study, will you be able to break out safety data between the initial titration phase and the maintenance period?
A: (Brian Lian, President and CEO) Yes, we hope to break out that initial period versus the maintenance period. It's an important question to understand how reducing dose frequency at higher levels feeds into the tolerability profile during the maintenance period.
Q: For the Phase III oral trial expected to initiate in Q4, what are some of the trial design elements you are still working through?
A: (Brian Lian, President and CEO) We are pretty set on the designs. It will be two studies, smaller and shorter in duration than the VANQUISH studies, with lower expense. The titration windows will likely stick with the common 4-week cadence. The main work is getting the manufacturing of the tablets ready.
Q: For the DACRA program (VK3019), is there a clear threshold for a go/no-go decision, for example, if it doesn't show much differentiation over VK2735?
A: (Brian Lian, President and CEO) It's hard to make decisions based on a single ascending dose (SAD) study unless there are obvious safety concerns. We will need to get through the multiple ascending dose (MAD) portion, which will follow the SAD, to know the answer, likely in the 2027 timeframe.
Q: How are you thinking about the DACRA program (VK3019) long term, as a monotherapy versus a combination partner with VK2735?
A: (Brian Lian, President and CEO) The mechanism has a role as both a stand-alone and in combination. As a stand-alone, it could be for patients needing 8-10% weight loss or those intolerant to GLP-1s. In combination, adding an amylin onto a GLP-1 typically shows a 40-50% improvement in efficacy, which could be industry-leading. The combination will likely follow the single-agent development.
Q: In the VANQUISH studies, are you implementing any measures to ensure patients report off-trial usage of incretins to avoid a surprising placebo effect?
A: (Brian Lian, President and CEO) GLP-1 use is an exclusion criteria and is not allowed in the study. We have not heard from our sites or investigators that this is an issue, and we were a bit surprised by reports of compounded use in other trials.
Q: For the maintenance study, should we expect comparable weight loss at week 21 to the 13.1% placebo-adjusted weight loss seen in the Phase II trial?
A: (Brian Lian, President and CEO) It's hard to do cross-trial comparisons due to different titration rates. I would expect it to be in the range of the 13-week study. More important than the number is the trajectory—whether it is plateauing or continuing, as that is a key observation.
Q: For the oral Phase III trial, should we think of the design as similar to the oral sema OASIS-1 obesity study?
A: (Brian Lian, President and CEO) Broadly speaking, yes, in that neighborhood. We've said it will be about 75% smaller than the VANQUISH study, so that's not a bad guess.
Q: Regarding the transition from a vial and syringe to an auto-injector in the VANQUISH studies, have you received any early feedback?
A: (Brian Lian, President and CEO) The transition has been pretty smooth. In VANQUISH-1, everyone is now on an auto-injector, and almost everyone in VANQUISH-2 is as well. It has helped reduce the trial burden, as visits dropped from four per month to one per month.
Q: How does your amylin program (VK3019) differ from others in development, and how quickly can you move to combo dosing with VK2735?
A: (Brian Lian, President and CEO) It's a novel compound that appeared very potent in animal studies, more potent than the most advanced amylin agonist today. In obese primates, it seemed more potent than VK2735. As for the combination, entering the clinic with any sort of combo product wouldn't be until next year at the earliest.
Q: For the oral portion of the maintenance study, do you expect a similar number of cohorts as in the injectable portion?
A: (Brian Lian, President and CEO) Yes, we will look at multiple doses. The number of arms will be very similar to the VANQUISH study. We will provide all details when we initiate the study in the fourth quarter.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
